【治療編】～2026年改訂版感染性心内膜炎診療ガイドラインを読む～

This is from the "Infectious Disease Anecdotes" talk by ID Kasahara and DJ Yamamoto, held on Wednesday, April 1, 2026. 00:05 Introduction: Overview of the IE Guidelines 2026 Revision 02:31 Principles of Antimicrobial Therapy and How to Count the Duration of Administration 05:25 Importance of Blood Cultures: Culture Period and Definition of Negative Results 10:44 Assessment of Treatment Efficacy: Blood Culture and Clinical Symptoms 14:45 Long-Term Suppression Therapy: Concepts of Suppression Therapy 18:14 Estimation of Causative Bacteria: Evaluation of Entry Channels and Patient Background 19:19 Streptococci: Characteristics of Different Bacterial Species and Risk of IE Complications 26:15 Treatment of Streptococci: Regimen for Proprietary Valves and Prosthetic Valves 34:45 Staphylococcus aureus: Comparison of Cefazolin and CTRX 46:51 MRSA Treatment: Pros and Cons of Combining Rifampicin and Points to Note 55:11 Treatment of Enterococci: CTRX Combination and Issues in Dosage Design 01:04:14 Surgical Treatment: Review of the Timing of Surgery in Cases Complicated with Cerebral Hemorrhage 01:08:33 Special Conditions: TAVI, Device, and Artificial Blood Vessel Infection 01:13:51 Oral Switch Therapy: POET Trial and Future Prospects